急性髓系白血病中乳腺癌耐药蛋白基因表达与临床意义

Expression of BCRP gene and its clinical significance in patients with acute myeloid leukemia

摘要:

目的  研究急性髓细胞白血病（AML）患者乳腺癌耐药蛋白（BCRP）基因的表达以及在预后判断中的意义。方法  构建实时定量PCR检测BCRP基因表达的技术，定量检测20例初治组AML患者、20例完全缓解组AML患者及20例难治复发组AML患者BCRP基因的表达水平，分析其在AML患者和非血液系统恶性肿瘤患者中的差异及与临床疗效的关系。结果  急性髓系白血病患者中BCRP的表达高于对照组（P <0.01），初治组、完全缓解组、难治复发组的BCRP表达均存在差异（P <0.01），其中难治复发组表达最高，初治组次之，完全缓解组最低。结论  BCRP基因在急性髓系白血病患者中表达增高，BCRP的表达水平可能是疾病进展的重要标志，可能是AML的独立危险因素。

Abstract:

Objective To explore the expression and prognostic value of breast cancer resistance protein (BCRP) gene in acute myeloid leukemia (AML). Methods Real time quantitative polymerase chain reaction (RT-PCR) method was performed to detect the mRNA of BCRP in AML group (n = 60) and non-hematologic malignancy group (n = 20). The difference in the BCRP expression of both groups was studied and its correlation with clinical effect was analyzed. Results The BCRP gene expression level in the AML patients was statistically higher than that in the control group (P < 0.01). Significant difference was found among the newly-diagnosed AML group, the relapsed AML group and the complete remission (CR) AML group and the control group (P < 0.01). The BCRP gene expression level was different in different disease stages with the highest level in the relapsed group and the lowest in the complete-remission group. Conclusions BCRP gene expression increases in AML patients. The expression level of BCRP gene can be a useful biomarker for evaluation of AML progression, and may be an independent risk factor of AML.